A detailed history of Harbor Capital Advisors, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 87,302 shares of ASND stock, worth $11.9 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
87,302
Previous 52,200 67.25%
Holding current value
$11.9 Million
Previous $7.12 Million 83.1%
% of portfolio
0.57%
Previous 0.54%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$113.0 - $153.43 $3.97 Million - $5.39 Million
35,102 Added 67.25%
87,302 $13 Million
Q2 2024

Jul 09, 2024

BUY
$121.07 - $153.67 $3.66 Million - $4.64 Million
30,194 Added 137.21%
52,200 $7.12 Million
Q1 2024

May 13, 2024

BUY
$123.45 - $159.4 $1.22 Million - $1.58 Million
9,921 Added 82.09%
22,006 $3.33 Million
Q4 2023

Jan 08, 2024

SELL
$86.1 - $127.36 $176,505 - $261,088
-2,050 Reduced 14.5%
12,085 $1.52 Million
Q3 2023

Oct 20, 2023

BUY
$86.5 - $103.97 $180,958 - $217,505
2,092 Added 17.37%
14,135 $1.32 Million
Q2 2023

Jul 11, 2023

SELL
$69.96 - $97.84 $11,053 - $15,458
-158 Reduced 1.29%
12,043 $1.07 Million
Q1 2023

Apr 26, 2023

SELL
$104.9 - $126.78 $105,844 - $127,921
-1,009 Reduced 7.64%
12,201 $1.31 Million
Q4 2022

Jan 20, 2023

SELL
$99.42 - $131.97 $28,334 - $37,611
-285 Reduced 2.11%
13,210 $0
Q3 2022

Oct 28, 2022

SELL
$84.03 - $110.23 $125,372 - $164,463
-1,492 Reduced 9.96%
13,495 $1.39 Million
Q2 2022

Jul 26, 2022

SELL
$78.08 - $117.61 $3,123 - $4,704
-40 Reduced 0.27%
14,987 $1.39 Million
Q1 2022

Apr 28, 2022

SELL
$102.18 - $135.75 $223,672 - $297,156
-2,189 Reduced 12.71%
15,027 $1.76 Million
Q4 2021

Feb 04, 2022

BUY
$127.1 - $169.66 $2.19 Million - $2.92 Million
17,216 New
17,216 $2.32 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Harbor Capital Advisors, Inc. Portfolio

Follow Harbor Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.